These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38445468)

  • 1. Therapeutic cysteine protease inhibitors: a patent review (2018-present).
    Barchielli G; Capperucci A; Tanini D
    Expert Opin Ther Pat; 2024; 34(1-2):17-49. PubMed ID: 38445468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
    Capasso C; Nocentini A; Supuran CT
    Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Patent Review on SARS Coronavirus Main Protease (3CL
    Chia CSB; Xu W; Shuyi Ng P
    ChemMedChem; 2022 Jan; 17(1):e202100576. PubMed ID: 34651447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Patent Review on SARS Coronavirus Papain-Like Protease (PL
    Brian Chia CS; Pheng Lim S
    ChemMedChem; 2023 Aug; 18(16):e202300216. PubMed ID: 37248169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors targeting coronavirus and filovirus entry.
    Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
    Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19).
    De SK
    Curr Med Chem; 2024; 31(9):1165-1169. PubMed ID: 37211851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.
    Li D; Luan J; Zhang L
    Biochem Biophys Res Commun; 2021 Jan; 538():72-79. PubMed ID: 33276953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV.
    Park JY; Ko JA; Kim DW; Kim YM; Kwon HJ; Jeong HJ; Kim CY; Park KH; Lee WS; Ryu YB
    J Enzyme Inhib Med Chem; 2016; 31(1):23-30. PubMed ID: 25683083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors.
    Falke S; Lieske J; Herrmann A; Loboda J; Karničar K; Günther S; Reinke PYA; Ewert W; Usenik A; Lindič N; Sekirnik A; Dretnik K; Tsuge H; Turk V; Chapman HN; Hinrichs W; Ebert G; Turk D; Meents A
    J Med Chem; 2024 May; 67(9):7048-7067. PubMed ID: 38630165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
    Amin SA; Banerjee S; Gayen S; Jha T
    Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
    Nicoll-Griffith DA
    Expert Opin Drug Discov; 2012 Apr; 7(4):353-66. PubMed ID: 22458506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Repurposing for the SARS-CoV-2 Papain-Like Protease.
    Cho CC; Li SG; Lalonde TJ; Yang KS; Yu G; Qiao Y; Xu S; Ray Liu W
    ChemMedChem; 2022 Jan; 17(1):e202100455. PubMed ID: 34423563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revealing the inhibitory potential of Yersinia enterocolitica on cysteine proteases of the papain family.
    Kędzior M; Pawlak A; Seredyński R; Bania J; Platt-Samoraj A; Czemplik M; Klausa E; Bugla-Płoskońska G; Gutowicz J
    Microbiol Res; 2018 Mar; 207():211-225. PubMed ID: 29458857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
    Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
    Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
    Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
    Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
    Wang HM; Liang PH
    Expert Opin Ther Pat; 2010 Jan; 20(1):59-71. PubMed ID: 20021285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
    Cianni L; Feldmann CW; Gilberg E; Gütschow M; Juliano L; Leitão A; Bajorath J; Montanari CA
    J Med Chem; 2019 Dec; 62(23):10497-10525. PubMed ID: 31361135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus.
    Cheng KW; Cheng SC; Chen WY; Lin MH; Chuang SJ; Cheng IH; Sun CY; Chou CY
    Antiviral Res; 2015 Mar; 115():9-16. PubMed ID: 25542975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.